Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

TL1A Transgenic Mice for the Study of Inflammatory Bowel Disease (IBD) and Allergic-Type Immune Responses

Posted Aug 29 2011 8:00pm

Description of Invention:
TL1A is a TNF family cytokine that co-stimulates T-cell proliferation and cytokine production through its interactions with the TNF family receptor DR3. TL1A-DR3 interactions have been shown to be important for the development of autoimmune inflammatory diseases, including inflammatory bowel disease (IBD).

In order to probe the role of TL1A-DR3 interactions in IBD, NIAMS inventors have developed transgenic mice that constitutively express TL1A in T cells or in dendritic cells. These mice spontaneously develop inflammatory small bowel pathology that is IL-13 dependent, and that closely resembles intestinal responses to allergens and to nematode infection.

These mice represent a unique model for the study of IBD, and in particular, the role of IL-13 in the development of this disease. They may also be used as a platform for investigating agents that block TL1A-DR3 interactions and the pathology associated with chronic TL1A expression.

Applications:
  • Studies of small bowel inflammation/IBD
  • Studies of the role of TL1A-DR3 interactions in the development of autoimmune inflammatory disease
  • Investigation of TL1A-DR3 blocking agents for the treatment of IBD or other TL1A-DR3 dependent diseases


Advantages:
  • Lines available with transgene expressed in T cells (under CD2 promoter) or dendritic cells (CD11c promoter)
  • Models are IL-13 dependent
  • No major defects in systemic immunity


Development Status:
In vivo data available (animal)

Inventors:
Richard M Siegel (NIAMS)
Francoise Meylan (NIAMS)


Patent Status:
HHS, Reference No. E-072-2011/0

Research Tool — Patent protection is not being pursued for this technology.

Related Technologies:
US, Application No. 11/972,395 filed 10 Jan 2008, Reference No. E-011-2007/0
US, Application No. 61/488,671 filed 20 May 2011, Reference No. E-073-2011/0
US, Application No. 60/879,668 filed 10 Jan 2007, Reference No. E-011-2007/0


Relevant Publication:
  1. Meylan F, et al. [ PMID 20980995 ]
  2. Meylan F, et al. [ PMID 18571443 ]


Collaborative Research Opportunity:
The National Institute of Arthritis and Musculoskeletal and Skin Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize TL1A Transgenic Mice. For collaboration opportunities, please contact Cecilia Pazman at pazmance@mail.nih.gov .


For Licensing Information Please Contact:
Tara Kirby Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: tk200h@nih.gov
Phone: 301-435-4426
Fax: 301-402-0220


Ref No: 2308

Updated: 08/2011

Post a comment
Write a comment:

Related Searches